Cervomed announces 32-week data from rewind-lb trial extension phase showing neflamapimod's sustained effect on slowing clinical progression in patients with dementia with lewy bodies and associated reduction in a key plasma biomarker of neurodegeneration

Based on the primary endpoint of clinical dementia rating sum of boxes (cdr-sb), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at week 32 of treatment (p=0.0037). this risk reduction improved to 64% (p=0.0001) among patients who have minimal evidence of ad co-pathology (ptau181 < 2.2 pg/ml at screening)
CRVO Ratings Summary
CRVO Quant Ranking